Dr. Eugenia Prohin is psychiatrist by training and a remarkable scholar. Since very early in her career, Eugenia got involved not only in clinical work, but also in teaching, research projects including those with international partners, and in the development of national guidelines and treatment protocols. Her passion for scientific development was hey in her decision of dedicating herself to clinical research, and in 2017 she became lead investigator in neuroscience at ARENSIA. Aside from her lead specialty, Eugenia is also expert in pharmacology, immunology, and oncology. She has qualified specialization courses form Harvard University in Pharmacology, Immuno-Oncology and Cancer Genomic, and also completed the School of Neuropsychopharmacology (ECNP, Oxford University). Eugenia is currently in the process of obtaining a PhD from Charles University in Prague. Her medical knowledge together with her interest in excellent scientific methodology, as well as  her understanding of various patient populations and their specifics make her a highly valued partner for clinical trial protocol development. At the side of Dr. Bischoff, Dr. Prohin coordinates Corporate Clinical Operations (CCO), bringing together Medical Directors of al ARENISA Clinics to develop and maintain the highest standards of quality  in clinical research, and align how we apply these standards in detail to every clinical trial conducted in ARENISA Clinics. Simultaneously, CCO working groups are perfecting existing solutions and are identifying and implementing new ones.